Greg Zante

Chief Financial Officer, Viking Therapeutics, Inc.

Search every verified Greg Zante interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Greg Zante, Chief Financial Officer of Viking Therapeutics, participated in the company’s Q4 2024 earnings call on February 5, 2025. During the call, he discussed the company’s planned phase three studies for its obesity program, stating that the trials would include at least 4,500 participants and would be conducted in obese subjects and obese subjects with type 2 diabetes. He noted that multiple doses would be used and that further details on the study design would be provided upon trial initiation. Zante also addressed questions about the company’s product candidates and manufacturing capabilities. He commented on the characterization of certain compounds, indicating that the most promising ones have a balanced profile between calcitonin and amylin receptors. Additionally, he discussed scalability of peptide production, stating that while peptide chemistry is relatively simple, scalability is the main challenge, and expressed confidence in the company’s ability to achieve production scale supporting a multi-billion dollar franchise.